Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.
According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.
Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.